CEM24

ESU Course - new developments in stone treatment
ROOM HS2

• 5’ European School of Urology: A unique possibility
  for urological education | E. Liatsikos (GR)

• 20’ EAU Guidelines recommendations on stone treatment | C. Seitz (AT)

• 20’ Combined intrarenal surgery – Is this the way to go? | E. Liatsikos (GR)

• 20’ Technological developments in flexible intrarenal surgery | C. Seitz (AT)

• 20’ Mini PCNL – A tool or a tale? | E. Liatsikos (GR)

• 35’ Interactive case discussion on Complications of stone surgery | E. Liatsikos (GR) C. Seitz (AT)  

Workshop I - Hands on endoscopic surgery
ROOM 21+OP4
J. Veser (AT), D. Mun (AT), V. Jahrreiss (AT), D. D'Andrea (AT), M. Kępiński (PL)

Workshop I - Hands on endoscopic surgery
ROOM 21+OP4
J. Veser (AT), D. Mun (AT), V. Jahrreiss (AT), D. D'Andrea (AT), M. Kępiński (PL)

Workshop II - Case-based update on metastatic prostate cancer  
ROOM 24

• 45’ Metastatic hormone-sensitive prostate cancer (mHSPC) | H. Ofner (AT)
• 45’ Castration-resistant prostate cancer (CRPC) | G. Kramer (AT)
• 30’ Genetic testing and therapy | J. Krauter (AT)

Workshop III - Semi-live prostate enucleation for BPE    
ROOM 29

• 20’ Why do we enucleate – History, body of evidence and rational | S. Ahyai (AT)
• 20’ Enucleation is enucleation is enucleation – energy sources? | L. Lusuardi (AT)
• 20’ How to shorten the learning curve? | D. Enikeev (AT)
• 20’ Tipps and tricks of HoLEP | S. Ahyai (AT)
• 20’ Tipps and tricks of bipolar EP | L. Lusuardi (AT)
• 20’ Tipps and tricks of ThuFLEP | D. Enikeev (AT)

Workshop IV - Surgical tips & tricks in uro-oncology  
ROOM 25

• 30’ Retroperitoneal lymphadenectomy | K. Gust (AT)   
• 30’ Radical prostatectomy, robotic | M. Remzi (AT)
• 30’ Radical cystectomy, robotic | J. Dobruch (PL)
• 30’ Partial nephrectomy, robotic | M. Hora (CZ)

with food (moderated poster walk starts 18:00-19:00)
Poster viewing from 13:00-19:00

Shahrokh Shariat (AT), Marek Babjuk (CZ), Igor Tomašković (HR), Peter Nyirády (HU),
Piotr Chlosta (PL),  Martha Orsolya (RO), Tomaž Smrkolj (SI), Ivan Minčík (SK)

Chairs: P. Chlosta (PL), P. Nyiradi (HU), I. Sinescu (RO)

• 8:30-8:35  PCa of intermediate risk profile - case & voting | P. Rajwa (PL)
• 8:37-8:42  Pro: Radical prostatectomy | C. Mirvald (RO)
• 8:44-8:49  Pro: Radiation therapy | F. Lakosi (HU)
• 8:51-8:56  Pro: Focal therapy | N. Hübner (AT)
• 8:58-9:03  Recurrence after focal therapy - case & voting | P. Rajwa (PL)
• 9:05-9:10   Pro: Salvage radical prostatectomy | K. Krpina (HR)
• 9:12-9:17   pT3a N0/8 at salvage RP, PSA persistence,
  PSMA PET CT: 2 LN metastases - case & voting | P. Rajwa (PL)
• 9:19-9:24    Pro: Salvage radiation therapy | P. Dubinský (SK)
• 9:26-9:31    Pro: Radio-guided salvage lymphadenectomy | R. Pantar (SI)
• 9:33-9:38   Pro: ADT + Enzalutamide | J. Franke (AT)
• 9:40-9:45   Salvage lymphadenectomy but PSA recurrence with
  PET PSMA metachronous singular bone metastasis - case & voting
  | P. Rajwa (PL)
• 9:47-09:52   Pro: ADT + ARTA  | A. Horváth(HU)      
• 09:54-09:59  Pro: ADT + ARTA + docetaxel | J. Szalontai (HU)
• 10:01-10:06  Pro: Genetic testing | I. Pezelj (HR)
• 10:08-10:13  Pro: Metastasis - directed radiation therapy | M. Miszczyk (PL)
• 10:15-10:20  ADT + ARTA but PSA rise, liver metastasis - case & voting
  | P. Rajwa (PL)
• 10:22-10:27   Pro: Chemotherapy | M. Ladurner (AT)
• 10:29-10:34   Pro: Radioligand therapy | E. Takacsova (SK)
• 10:36-10:41   Pro: Parp - inhibitor in BRCA negative | T. Fazekas (HU)
• 10:43-11:00   Take home – 5 most important messages & discussion | G. Kramer (AT)               

​​​Chairs: S. Ahyai (AT), I. Minčik (SK), T. Smrkolj (SI)

• 11:30- 11:37  Are there any limits to RIRS: is PCNL obsolete? | A. Szendrői (HU)
• 11:40-11:47   Enucleation for BPE – What is new? | T. Hradec (CZ)
• 11:50-11:57   Landscape of surgical alternatives for large BPE | S. Lenart (AT)
• 12:00-12:07  HoYag vs TFL. Which laser performs better in lithotripsy? | D.Enikeev(AT)
• 12:10-12:17   Anterior urethral strictures - What can we do? | Z. Saratlija (HR)
• 12:20-12:27   Sperm quality deterioration: Is it real and what can we do? | A. Szabó (HU)

Chairs: P. Chlosta (PL), H. Fajkovic (AT), M. Orsolya (RO)
Judges: Harun Fajkovic (AT), Milan Hora (CZ), Igor Tomašković (HR),
Peter Nyirády (HU), Mohammad Abufaraj (JOR), Piotr Chlosta (PL), Martha Orsolya(RO), Tomaž Smrkolj (SI), Ivan Minčík (SK)

• 13:00-13:05     Anna K. Czech: The assessment of bladder cancer resectability with bimanual palpation
• 13:07-13:12     Samra Jasarevic: Intermediate- and long-term results after ATOMS (Adjustable Transobturator Male System®) implantation
• 13:14-13:19      Hanna Hagen: Penile inversion vaginoplasty in transgender women: peri- and postoperative complications and sexual function outcome
• 13:21-13:26      Cosmin Cozma: Retrograde ureteroscopic treatment for renal lithiasis with sizes between 2 and 4 cm
• 13:28-13:33       Tamás Fazekas: Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis
• 13:35-13:40      Oana Moldoveanu: Impact of preoperative serum levels of CYFRA 21-1 on overall survival of patients with cystectomy for muscle-invasive bladder cancer
• 13:42-13:47      Jan Svihra: The comparison of bilateral and unilateral percutaneous nephrolithotomy, meta-analysis 
• 13:49-13:54     Maša Alfirević: The association of quality of life (QoL) with urinary diversion
• 13:56-14:01      Iris Ertl: Clofarabine displays a distinctly superior therapeutic window over gemcitabine in preclinical bladder cancer models
• 14:03-14:08     Marcin Chlosta: Assessment of Briganti and other nomograms in salvage setting

Chairs: M. Babjuk (CZ), J. Dobruch (PL), I. Tomašković (HR),  

• 14:30-14:35  Intermediate risk NMIBC- case & voting | A. Brisuda (CZ)
• 14:37-14:42 Pro: Chemoablation | E. Laukhtina (AT)
• 14:44-14:49  Pro: Urine - based biomarker in the surveillance | T. Smrkolj (SI)
• 14:51-14:56  Pro: Adjuvant intravesical chemotherapy | R. Tomaškin (SK)
• 14:58-15:03  Pro: Adjuvant intravesical BCG therapy | D. Georgescu (RO)
• 15:05-15:10  Pro: En bloc TURBT | D. D’Andrea (AT)
• 15:12-15:17 Adjuvant MMC but progression to pT1 HG 5%         
  micropapillary- case & voting | A. Brisuda (CZ)
• 15:19-15:24  Pro: Adjuvant intravesical BCG therapy | J. Janša (SI)
• 15:26-15:31  Pro: Early radical cystectomy | R. Pantar (SI)
• 15:33-15:38  BCG unresponsive pT1 HG 5% micropapillary- case & voting
  | A. Brisuda (CZ)
• 15:40-15:45  Pro: Radical cystectomy | C.Leitsmann (AT)
• 15:47-15:52   Pro: Bladder-sparing intravesical therapies | O. Moldoveanu (RO)
• 15:54-15:59   Progression to cT2N0 HG, eGFR 65- case and voting
  | A. Brisuda (CZ)
• 16:01-16:06   Pro: Bladder preservation with radio chemotherapy
  | A. Andresanu (RO)
• 16:08-16:13  Pro: Radical cystectomy first | L. Discalicau (RO)
• 16:15-16:20  Pro: Neoadjuvant chemotherapy first | K. Oberneder (AT)
• 16:22-16:27   RC without neoadjuvant therapy pT3 N1, eGFR 60- case & voting | A. Brisuda (CZ)
• 16:29-16:34  Pro: Adjuvant cisplatin-based chemotherapy | K. Gronostaj (PL)
• 16:36-16:41   Pro: Adjuvant nivolumab | M. Hassler-Di Fratta (AT)
• 16:43-16:48  No therapy given; progression with lung metastasis;
  EGFR 60- case & voting | A. Brisuda (CZ)
• 16:50-16:55  Pro: Enfortumab vedotin + pembrolizumab | K. Gust (AT)       
• 16:57-17:10  Take home – 5 most important messages & discussion | A. Czech (PL)           

Chairs: M. Babjuk (CZ), D. Enikeev (AT), I. Sinescu (RO)
Judges: S. Shariat (AT), M. Hora (CZ), I. Tomašković (HR), P. Nyirády (HU), P. Chlosta (PL),
M. Orsolya (RO), T. Smrkolj (SI), I. Minčík (SK)

• 17:30 - 17:37   Austria: V. Jahrreiss:
  Outcomes of ureteroscopy and laser lithotripsy (URSL) in pediatric patients for large and very large stones  

• 17:40 - 17:47   Croatia: M. Alfirevic:
  Neoadjuvant or induction chemotherapy (N/IC) for bladder cancer: “Real world” experience

• 17:50 - 17:57   Czech Rep.: O. Příman:
  Visualization of prostate cancer prior to biopsy in era of modern imaging methods and modification of following local treatment

• 18:00 - 18:07   Hungary: I. Kocsmár:
  Molecular prediction of muscle invasion: Can we revise the grading and risk stratification of non-muscle invasive urothelial carcinomas?

• 18:10 - 18:17   Poland: P. Adamczyk:
  The new dilemma in personalized approach to radical cystectomy in muscle invasive bladder cancer patients

• 18:20 - 18:27   Romania: L. Maxim:
  High resolution micro - ultrasound or MRI in the diagnosis of prostate cancer  

• 18:30 - 18:37   Slovakia: O.  Gajdoš:

  Does the transrectal approach still have a place in the perineal biopsy era?
  - Our experience and outcomes.

• 18:40 - 18:47   Slovenia: K. Cerović:
  Tumor rupture during robot-assisted partial nephrectomy                

M. Babjuk (CZ)